Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Giles, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giles, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:815-816, 2002
© 2002 European Society for Medical Oncology

Editorial

How important are estimates of cancer prevalence?

G. Giles

CCRI, Cancer Epidemiology Centre, Anti-Cancer Council of Victoria, Carlton, Australia (E-mail: graham.giles@cancervic.org.au)

This edition of Annals of Oncology contains two related articles on cancer prevalence [1, 2]. The first describes the EUROPREVAL Project, its methods and some broad findings, while the second gives details of cancer prevalence estimates based on data from several European Cancer Registries. EUROPREVAL is a natural extension of another exercise in quantitative gigantism, the EUROCARE-2 study [3], and takes advantage of data obtained from the quality assurance programmes put in place, in this instance by 38 cancer registries in 17 countries.

One might ask why these papers have appeared in Annals of Oncology? First, EUROPREVAL represents a considerable scientific effort to measure a dimension of the cancer burden that is not immediately accessible from the more commonly available cancer incidence, mortality and survival trends. As . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
G. Gatta, R. Capocaccia, F. Berrino, M. R. Ruzza, P. Contiero, and the EUROPREVAL Working Group
Colon cancer prevalence and estimation of differing care needs of colon cancer patients
Ann. Onc., July 1, 2004; 15(7): 1136 - 1142.
[Abstract] [Full Text] [PDF]